Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8297575 | 0.94 | GRM5 (0.67) | GRM5DPP4DPP7MAPTALDH1A1 | |
| SCHEMBL8298896 | 0.92 | GRM5 (0.63) | GRM5DPP4DPP7MAPTALDH1A1 | |
| SCHEMBL23236018 | 0.85 | DPP4 (0.47) | GRM5DPP4DPP7MAPTALDH1A1 | |
| SCHEMBL21811036 | 0.85 | DPP4 (0.47) | GRM5DPP4DPP7MAPTALDH1A1 | |
| SCHEMBL21811037 | 0.85 | DPP4 (0.47) | GRM5DPP4DPP7MAPTALDH1A1 | |
| SCHEMBL12126174 | 0.83 | ALDH1A1 (0.48) | GRM5DPP4DPP7MAPTALDH1A1 | |
| SCHEMBL15204677 | 0.80 | SMN1; SMN2 (0.48) | GRM5DPP4DPP7MAPTALDH1A1 | |
| SCHEMBL15204675 | 0.80 | SMN1; SMN2 (0.48) | GRM5DPP4DPP7MAPTALDH1A1 | |
| SCHEMBL12126350 | 0.79 | ALDH1A1 (0.50) | MAPTALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL23236057 | 0.78 | DPP4 (0.47) | GRM5DPP4DPP7MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058292-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7767699-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CHRNA10, ACHE, SNCA | GRM5 336/4885DPP4 1809/4885DPP7 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.